Orphan nuclear receptor NR2F6 acts as an essential gatekeeper of Th17 CD4⁺ T cell effector functions

Natascha Hermann-Kleiter* and Gottfried Baier*

Abstract

Members of the evolutionarily conserved family of the chicken ovalbumin upstream promoter transcription factor NR2F/COUP-TF orphan receptors have been implicated in lymphocyte biology, ranging from activation to differentiation and elicitation of immune effector functions. In particular, a CD4⁺ T cell intrinsic and non-redundant function of NR2F6 as a potent and selective repressor of the transcription of the pro-inflammatory cytokines interleukin (Il) 2, interferon y (Ifng) and consequently of Th helper (Th)17 CD4⁺ T cell-mediated autoimmune disorders has been discovered. NR2F6 serves as an antigen receptor signaling threshold-regulated barrier against autoimmunity where NR2F6 is part of a negative feedback loop that limits inflammatory tissue damage induced by weakly immunogenic antigens such as self-antigens. Under such low affinity antigen receptor stimulation, NR2F6 appears as a prototypical repressor that functions to "lock out" harmful Th17 lineage effector transcription. Mechanistically, only sustained high affinity antigen receptor-induced protein kinase C (PKC)-mediated phosphorylation has been shown to inactivate NR2F6, thereby displacing pre-bound NR2F6 from the DNA and, subsequently, allowing for robust NFAT/AP-1- and RORγt-mediated cytokine transcription. The NR2F6 target gene repertoire thus identifies a general anti-inflammatory gatekeeper role for this orphan receptor. Investigating these signaling pathway(s) will enable a greater knowledge of the genetic, immune, and environmental mechanisms that lead to chronic inflammation and of certain autoimmune disorders in a given individual.

Keywords: Autoimmune disease, Pro-inflammatory Th17 cells, Nuclear orphan receptors, Immune response balance and check, NR2F-orphan receptor family, NFAT, AP-1, RORγt, Transcriptional regulation

Introduction

The immune system protects our bodies against invasion by pathogens of viral, bacterial, fungal and parasitic origin and against growth of neoplastic cells. The intensity of the adaptive immune responses must be tightly regulated in terms of class and duration to allow the proper production of immunoregulatory cytokines or chemokines by T lymphocyte subsets and the differentiation of B cells that are able to produce various antibody classes. Subsequently, the interaction between innate and adaptive immune cells provides the best protection for the organism while preventing, as far as possible, collateral damage to bystander tissue. However, because it is a tightrope-walk situation, this delicate balance can be subverted by severe infections, disruption of tissue integrity or genetic susceptibility. Under such conditions, acute immunological pathology such as persistent infection, chronic inflammatory disease and/or autoimmunity may occur.
To be able to modulate such immune diseases clinically, it is essential to both fully understand the positive and negative pathways that regulate immune homeostasis and to predict the adverse effects that could occur during host protection. It is well recognized that such immune cell signaling networks are strongly influenced by an array of distinct nuclear receptors (NRs). In humans the NR superfamily consists of 48 transcription factors from the steroid hormone, thyroid hormone, oxysterol as well as lipid receptors. In the immune system, NRs are involved in diverse processes such as development, activation, apoptosis, subset differentiation and homeostasis regulation. It is becoming increasingly clear that immune response outputs are orchestrated by both the expression level and the transcriptional activity of several members of the NR family including the glucocorticoid (GR/NR3C1), estrogen (ER/NR3A1&2), vitamin-D3 (VDR3/NR1I1), nuclear receptor subfamily 4, group A, member 2 (NR4A2), peroxisome proliferator-activated receptor γ (PPARY/NR1C3) or the retinoic acid receptors (RAR/NR1B1). Specifically, these NRs appear to allow a fine tuning of immune cellular processes to environmental changes such as external milieu signals and the cell intrinsic metabolic state during host protection [1-4]. Notably, NRs have been shown to be essential for both the pro-and anti-inflammatory processes in health and disease. Consistently, in both mice and humans, NR mutations have been specifically associated with immune deficiencies or autoimmunity [3,5-9].

Physiological roles of NR2F1 and NR2F2 in non-hematopoietic cells have been reviewed in detail lately and have been identified to be critical regulators in cell differentiation, tissue development, angiogenesis and metabolism [16,17]. The family member NR2F6 was not reviewed by Tsai [12,18,16] although it has been thought to be functionally closely related [15]. However, and unlike Nr2f1 and Nr2f2 knockout mice, Nr2f6-deficient mice are viable and fertile, and they have an underdeveloped locus coeruleus of the forebrain, which causes defects in nociception and in circadian clock behavior [19]. Despite its function in the central nervous system NR2F6 is also suggested to repress mouse renin, human oxytocin or rat LH gene transcription [20-24]. Additionally, NR2F6 has been found to be strongly over-expressed in colorectal cancer and to regulate the survival of tumor cells [25].

**Table 1 Nomenclature of mammalian NR2F-family members and their synonyms (according to http://www.ncbi.nlm.nih.gov)**

| NR2F1 | NR2F2 | NR2F6 |
|-------|-------|-------|
| ERBA-related protein Ear3 | Apolipoprotein regulatory protein 1, ARP1 | V-erbA-related protein 2; Ear2 |
| COUP transcription factor I or 2, COUP-TF I or 2 | COUP transcription factor II or 2, COUP-TF2, COUP-TFI, Tcfcoup2, COUPTF8 | COUP transcription factor 3, COUP-TF3 |
| V-erbA-related protein 3; avian erythroblast leukemia viral (v-erb-a) oncogene homolog-like 3; ErbAl3 | ADP-ribosylation factor related protein 1, Aprp1 | Avian erythroblast leukemia viral (v-erb-a) oncogene homolog-like 2, Erbal2 |
Nr2f2 deficiencies in mice are fatal and only conditional knockout mice are available for analysis: Owing to the relatively low levels of Nr2f1 and Nr2f2 transcripts in resting lymphocytes [27,31-33], when compared to, e.g., ovary, kidney or brain, such conditional knockouts for the immune compartment have not yet been generated.
However, low levels of expression might also imply that NR2F-family members are powerful regulators of immune cell activation and that expression of this protein family must be tightly controlled in lymphocytes. Because of this possibility and because, dependent upon the microenvironment, memory/effector T cells change expression profiles with their effector differentiation into a specialized subset, it remains a worthy goal to investigate the potential immune system roles of all NR2F-family members in more detail. In fact, signaling pathways that are known to be regulated by NR2F-family members in non-hematopoietic tissues, such as the RAR, TR, VDR, PPARγ, the arylhydrocarbon receptor (AhR), the forkhead box sub-group O (Foxo3a) and the hepatocyte nuclear factor 4 (HNF4/NR2A4) are well known to be critical also in adaptive immune responses [10,12,17,34-38]. NR2F2 generally is thought to functionally interact with many different signaling pathways such as Notch, β-catenin, transforming growth factor-β (TGFβ), HNF4α, runt related transcription factor (Runx) 2, PPARγ, CCAAT/enhancer binding protein (C/EBP) α, GATA, RARs or PPARα pathways [34,39-48]. Albeit that all these are known to be highly relevant in inflammatory and/or immune responses, a potential relevance of NR2F2 in specific immune cell subsets has not yet been investigated.

Nevertheless, several studies may indeed indicate a role for all three NR2F-family members in human immune function and in lymphomas and leukemia. Augmented NR2F1 expression has been identified in the pre-disease state of multiple sclerosis patients, potentially indicating a role in the development of autoimmune disease [49]. In the rare autosomal recessive immune disorder, called ICF syndrome (or Immunodeficiency, Centromere instability and Facial anomalies syndrome) microarray experiments and real-time RT-PCR assays revealed significant differences in RNA levels for NR2F2 in lymphoblasts from ICF patients [50]. In humans NR2F2 is strongly upregulated in CD4+ and CD8+ T cell lymphoma cells, while NR2F6 expression has been shown to be upregulated in lymph nodes [51]. In addition, NR2F6 is significantly upregulated in Anaplastic Large Cell lymphoma compared with Hodgkin lymphoma in human patients [52]. Finally, NR2F6 is deregulated in CD4+ T cells of adult T cell leukemia patients [53]. In preclinical models, NR2F6 has been suggested to regulate the maintenance of the clonogenic status within the cell hierarchy of the cancer cells [54]. While Nr2f6 is highly expressed in hematopoietic stem cells, its expression declines strongly upon normal hematopoietic differentiation as well as the transitions of KSL (c-kit−, sca−1−, lineage−) hematopoietic stem cell to an immature double negative (DN1) T cell stage and from DP to the CD8+ SP cells. Of note, Ichim et al., describes a candidate regulatory role of NR2F6 during T cell development. Bone marrow reconstitution experiments with forced overexpression of recombinant NR2F6 resulted in limited T cell development and decrease in thymus size and cellularity [55]. Additionally, NR2F6 expression has also been found to be significantly downregulated in CD19+ B cells of systemic lupus erythematosus patients [56].

NR2F6 appears to restrain Th17-dependent autoimmunity

In addition to its established role in the brain, recent data define NR2F6 as a critical regulatory factor in the adaptive immune system [57] and one of its key functions appears the repression of cytokine production in T cells. The ability of NR2F6 to reversibly suppress the transcription of the TCR/CD28-transactivated transcription factors such as the nuclear factor of activated T cells (NFAT) and the activating protein 1 (AP-1) mechanistically explains its ability to limit IL-2 and IFNγ production. Consistent with this observation, it is well documented that several other NRs, such as the steroid receptors, PPAR, RXR, RAR, and VDR repress the ability of NFAT and/or AP-1 to transcribe their target genes in T cells and this interference is the established basis for the anti-inflammatory actions of corticosteroids [58-63].

Examination of Nr2f6 expression revealed that Nr2f6 mRNA is upregulated in a subset of CD4+ T cells that are commonly known as T helper 17 (Th17) cells [57]. Indeed, in the experimental autoimmune encephalomyelitis (EAE) model, a significantly augmented disease progression of Nr2f6 knockout mice establishes a critical and non-redundant functional threshold mechanism of NR2F6 for repressing Th17 cell pathology both in vivo and in vitro [57]. When biochemically investigating the immune cell intrinsic NR2F6 signaling function(s), NR2F6 appears to counteract the calcium/calcineurin/NFAT-signaling pathway. Mechanistically, NR2F6 directly binds to multiple sites within the Il17a promoter locus and suppresses the DNA accessibility of endogenous NFAT in resting or suboptimally stimulated Th17 cells. In fact, an antagonistic association between NFAT and NR2F6 occupancy on common target genes in T cells strongly suggests a competitive interaction between these TFs. Indeed, NFAT was coimmunoprecipitated with NR2F6 in a DNA scaffold dependent manner, which indicates that these two TFs form a heterodimeric protein:protein complex when bound on DNA. This may either suggest a direct physical competition for high-affinity binding sites and/or subsequently, a transcriptional repression of NFAT by NR2F6. Consistent with this notion, both the physical protein:protein interaction with NFAT and the trans-repression mode of NR2F6 is critically dependent on the DNA-binding and the ligand-binding domains of NR2F6, at least when investigated upon coexpression of recombinant TFs in a T cell line [64].
In addition, NR2F6 also directly competes with the Th17 lineage nuclear orphan receptor RORγt for the DNA accessibility to the hormone response elements within the Il17a conserved noncoding sequences (CNS)2 promoter region (Figure 2) [64,65]. Similar to NR2F6, the nuclear receptors RAR, PPAR, LXR, VDR, GR and ER repress Th17 differentiation and protect against the EAE disease mouse model. Nevertheless, the lineage specific TFs that positively induce the differentiation of Th17 cells are RORγt and RORα [66-75]. This opposite behavior of i.e. RORγt might be explained by its DNA binding capability as a monomer whereas all the other NRs (that restrain Th17 cell functions) are described by their DNA binding capabilities as dimers, both as homo- or heterodimers [76,77].

Thus and although these few defined lineage TFs orchestrate synexpression gene clusters that serve in distinct pathways, lineage specificity and plasticity remains a product of the complex combinatorial regulation of gene transcription. Analogous to other pluripotent progenitor cells, particularly naïve CD4+ T cells face the challenge of balancing stability and plasticity in their gene expression programs as they differentiate into their highly specialized subsets under the influence of their microenvironment. Recent studies, have generated such a detailed insights into the complexity of T cell lineage differentiation programs especially for the Th17 lineage that appears to be controlled and limited by positive and negative feedback circuits [78,79]. Transcription initiation at sites that are occluded by nucleosomes and high-order chromatin structure is established to require mechanisms for making specific regions accessible to the appropriate regulators [80]. Consistently, chromatin accessibility analysis suggests that such TF complexes pioneer the access of additional TFs and, subsequently, further specify functional subset programming. In the presence of Th17-polarizing cytokines, STAT3, NR2F6 and RORγt are likely to be recruited to many of the same promoters. Intriguingly however, NR2F6 occupancy appears to also strongly overlap with that of NFAT. A long this line of argumentation, such an epigenetic chromatin remodeling role, especially for NFAT2, in transcriptional regulation has been suggested: Because NFAT2 is strongly upregulated in Th0 cells, it has been speculated that the NFAT-mediated pioneering function provides the T cell with plasticity to differentiate in multiple directions, depending on the cytokine environment [81]. Thus, whereas Th17 signals recruit signal-transducer and activator of transcription protein (STAT)3/RORγt to a subset of NFAT/AP-1 binding sites, Th1 or Th2 signals recruit STAT1/T-bet or STAT6/GATA-3 to other NFAT/AP-1 binding sites. Of note, especially Th17 cells are sensitive to low NFAT levels [82], albeit NFAT and AP-1 have also roles in other Th subsets [83]. Consistently, NR2F6 may serve as an integrated regulator of the defined Th17 helper cell lineage identity and/or plasticity that functions by repressing transcriptional programs at key gene loci.

Importantly, and in contrast to other NRs, constitutively lymphocyte-expressed NR2F6 is already prebound to its hormone response elements within i.e. the Il17a cytokine promoter loci in a resting state and thereby may simply inhibit the induced DNA binding capacities of activation-dependent TFs (see for our working model.

**Figure 2** The Il17a promoter and its regulation by orphan nuclear receptors. The interleukin (IL) 17a minimal promoter and conserved non-coding sequences (CNS) are controlled by the general transcriptional machinery and by several nuclear receptors. The DNA consensus binding sequences within the minimal and the CNS2 region of the Il17a promoter for NFAT and for nuclear receptors such as NR2F6 and RORγt are shown. Two orphan nuclear receptors, RORγt and NR2F6, thereby have key roles in Il17a gene regulation. Of note, NR2F6-family members form homo- or hetero-dimers that interact with co-binding partners that are either co-activators or co-repressors. These complexes bind to their consensus sequences (HRE) in the DNA to either inhibit or stimulate target gene transcription. NR2F6 thereby plays a fundamental role in the CD4+ T cell compartment by balancing Th17 differentiation and inflammation, as do several other nuclear receptors such as the Ah-R, RARs, PPARs, LXR, VDR, GR and ER. The lineage-specific master transcription factor RORγt is the only nuclear receptor established to enhance Th17 differentiation and restrains iTregs.
cartoon in Figure 3). The current experimental evidence thus might suggest that NR2F6 similarly affects responses by remodeling the chromatin landscape, which would critically control the subsequent recruitment of other TFs involved in regulating the expression of adjacent genes. Next to IL-17, Nr2f6-deficient T cells also repress IL-2 and IFNγ, which indicate that NR2F6 may serve as a more general gatekeeper by directly preoccupying binding sites for NFAT to prevent transcriptional activation [57]. This conveys an important message for Th17 subset selectivity and indicates that NR2F6 specifically counteracts the generation of the highly pathogenic Th17 cell type and decreases the risk of promoting autoimmunity [57]. Intriguingly and of note, NR2F6 however appears to alter the transcription levels of only a selected subset of genes rather than promote large-scale changes in gene expression. The exact mode of action of NR2F6 function, however, remains further detailed investigations. In contrast to Th17 cells, NR2F6 appears dispensable, or at least less critical, for Th1 and Th2 functions. This renders NR2F6 an exceptional drug target because therapeutic intervention would not be expected to perturb the generic regulatory programs that are shared by other immune cell types. In this context, it will be necessary to compare the global distributions of NR2F6 and NFAT and of lineage-specifying TFs in Th17, iTreg, Th1 and Th2 cells. NR2F6 might thereby appear as a prototypical repressor candidate that functions to specifically antagonizes Th17 lineage programs.

**NR2F6 is itself regulated**

**Nr2f6 mRNA**

Because CD4+ T lymphocytes can differentiate into several diverse subsets depending on microenvironmental milieu factors and similarly to the FOXO transcription factor family, expression of the NR2F-family might influences cellular potential [84]. We showed that the expression of NR2F6 was regulated upon TCR/CD28 stimulation and cytokines in the Th17 polarization milieu strongly increased Nr2f6 expression in T cells [57]. Thus, transcriptional regulators of the Nr2f6 locus, albeit currently undefined, appear to be induced in response to Th17-polarizing conditions. In silico analysis strongly indicates, that the Nr2f6 promoter may have functional STAT and NR sites [85].

**Post-translational modification (PTM) of NR2F6**

Antigen receptor-induced protein kinase (PK)C-mediated phosphorylation has been shown to inactivate NR2F6, thereby allowing for robust cytokine responses [57]. Mechanistically, Ser-83, which is located within the DBD of NR2F6, appears to be the main phosphorylation site upon TCR stimulation to abrogate the DNA-binding capacities of NR2F6 and subsequently allows NFAT/AP-1 binding at the given promoters. Thus, only phosphorylation of NR2F6, which is mediated by a sustained PKC activity downstream of full and robust TCR/CD28 activation, promotes unopposed NFAT and/or RORγt-mediated DNA binding at the critical cytokine gene loci such as Il2 and Il17a. Similarly, IL-2 secretion is
established to be inhibited by several other NRs, such as the ER (NR3A), RAR (NR1B), PPARs (NR1C), LXR (NR1H3) VDR (NR1I1), and GR (NR3C1) [61,86-90], whereas AhR activates the Il2 promoter [91]. Similarly to NR2F6, the DNA binding domains of other nuclear receptors, such as Nur77 (NR4A1), RARα (NR1B1), ERα (NR3A1), or the VDR (NR1I1), are directly phosphorylated by PKC or PKA as reviewed previously [92,93]. A significant difference between the formerly mentioned NRs and NR2F6 is the constitutive presence of NR2F6 at its hormone response element (HRE) of the DNA in resting cells, whereas the other NRs are activated via environmental stimuli and subsequently adapt the cell to the microenvironment through their DNA binding capability. Additionally, the number and diversity of other PTM covalent modifications of NR2F6, such as acetylation, ubiquitination or sumoylation which are well known to shape nuclear receptor activity [9,94], have just begun to be analyzed.

NR2F6-Ligand?
Although the NR2F-family remains defined as orphan NRs, a significant interest in the identification of the detailed molecular mechanisms and identification of endogenous ligands that may regulate these NRs exists. Of note, a recent study has shown that NR2F2 is a retinoic acid-activated receptor [95]. This ligand-regulated feature of NR2F2 (albeit retinoic acid has a rather low affinity) has left open the possibility that, although currently undefined, endogenous NR2F-family specific ligands may exist as agonists or antagonists and may modulate the functions of NR2F-family members. In this regard, the findings that high levels of retinoic acid trigger iTreg formation might be relevant [95]. Detailed studies are now urgently needed to determine the physiological consequences of mRNA regulation, covalent PTM modifications, and the existence of modulatory function(s) of endogenous ligands of NR2F6 function in detail.

NR2F6 as a drug target in molecular medicine
Environmental factors and gender undoubtedly play key roles in the susceptibility to autoimmune diseases, but clearly genetic disposition is also important. These NR2F6–mediated transrepression is proposed to have roles in controlling both the initiation, magnitude and duration of pro-inflammatory gene expression, and, thus, in targeting NR2F6-specific mechanisms, both local and systemic inflammation appear amenable to clinical manipulation. NR2F6 could potentially represent such a genetic risk factor for the development of autoimmune diseases through its regulation of pathogenic Th17 cells. In deed, NR2F6 has been identified as a type 1 diabetes susceptible SNP (http://arxiv.org/pdf/1404.4482.pdf) and as a risk allele in autoimmune leukocytes [96]. It now will be interesting to further validate this potential genetic association of allelic NR2F-family variants/SNPs with health and disease.

Of note, nuclear receptors have been a rich source of drug targets, especially for inflammation-mediated diseases but also in lipid, carbohydrate and energy homeostasis [32]. Over the past few years, significant breakthroughs in the identification of ligands both from natural as and from synthetic sources have occurred, as reviewed by Burris [97]. The newly defined repressor, NR2F6, may be a compelling and well-validated new target for regulating the Th17 lineage balance and for switching pathogenic Th17 into non-pathogenic cells. Furthermore, the effect would be largely specific for Th17 cells because we did observe comparable effector response outcomes during the differentiation of the other CD4+ T cell subset. In addition, the lack of maintenance function of NR2F6 in adult organs renders it a potentially safe target for the treatment of immune diseases.

Taken together, this NR2F6-centered pathway identified may very well offer new targets that are aimed at blocking the generation of pathogenic Th17 cells for the treatment of autoimmune diseases. Although our current preclinical knowledge strengthens this hypothesis, the direct causality of NR2F6 and incidence of human autoimmune disease remains yet to be demonstrated (Table 2).

Conclusions
Here, we describe recent studies that extend our understanding of how the NR2F-family member NR2F6 exerts important regulatory roles in adaptive immunity. In our model, NR2F6 exerts its Th17-negative regulatory function as a transcriptional repressor that competes with Th17-positive transcription factors over binding sites, which is analogous to the action of other NRs. Importantly, however, NR2F6 appears to alter the transcription levels of only a very selected subset of genes rather than promoting large-scale changes in gene expression. Of note, NR2F6 may act differently on various promoters to modulate transcription, and its effect may be dependent upon epigenetics or possibly concurrent direct and indirect interactions between other proteins and NR2F6. NR2F6 might also share functions with its paralogs NR2F1 and NR2F2 in the repression of key cytokine mRNAs that control Th17 cells and systemic inflammation. Studies that include genome-wide approaches and detailed analyses of NR2F-family-dependent genetic programs will be essential to comprehensively understand the relationship between NR2F-family activity and distinct human diseases.

Nevertheless, our current functional model provides an excellent starting point for deciphering the underlying physical interactions with DNA binding profiles or
Table 2 Physiological functions of NR2F family members and their roles in disease

| Function               | NR2F1                                                                 | NR2F2                                                                 | NR2F6                                                                 |
|------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|
| **Immune system**      | **T cells** [27], http://www.immgen.org + + + +                       | **B cells** [27], http://www.immgen.org + + + +                       | **T cell development, activation thresholds, CD4+ Th17 autoimmunity, leukemia [51,53,54,57,64,98] + + + + + |
|                        | Autoimmunity, expressed CD4+/CD8+ and CD19+ cells [26,49]             | Autoimmunity, expressed CD4+/CD8+ and CD19+ cells [26,50,51]           |                                                                      |
|                        | CD4+ Th17 autoimmunity, leukemia [51,53,54,57,64,98]                   |                                                                      |                                                                      |
| **Development**        | **Embryo, eye, hair, ear, angiogenesis [99]**                         | ES cell differentiation, mesenchyme, angiogenesis, stomach, eye, osteoblast [34,100-102] |                                                                      |
|                        | **ES cell differentiation, mesenchyme, angiogenesis, vessel identity, cerebellum, lymphangiogenesis, stomach, eye, osteoblast [34,100-102]** |                                                                      |                                                                      |
| **Hormone regulation** | LHβ, Vegf, LH, receptor, RAR [103]                                   | LH receptor, oxytocin [22-24,104]                                      |                                                                      |
| **Cancer**             | Breast & prostate cancer, MC-lymphoma, metastasis, AML [43,105]       | Colorectal, survival [25,52,54,106]                                    |                                                                      |
| **Metabolism**         | Lipid uptake [41,103]                                                 | Insulin secretion, adipogenesis, energy metabolism                     | Lipid metabolism [107,108]                                           |
|                        |                                                                      |                                                                      |                                                                      |
| **CNS**                | Axons formation [109]                                                 |                                                                      | Circadian rhythm, nociception [19,110-112]                           |
|                        | Cortex patterning                                                    |                                                                      |                                                                      |
|                        | Fate specification                                                   |                                                                      |                                                                      |
| **Kidney**             | Reproduction                                                         | Reproduction                                                         | Reproduction [20,21,113]                                             |
| **Reproduction**       |                                                                      |                                                                      |                                                                      |

The expression pattern of the Nr2f gene family has been investigated in resting and activated T and B cells by the ImmGen Consortium (http://www.immgen.org). All Nr2f family members are expressed in diverse adaptive and innate immune cells. Of note, and as a general rule of thumb, the mRNA expression levels of Nr2f6 in hematopoietic cells are increased approximately twofold in comparison to the mRNA expression levels of Nr2f1 and Nr2f2 depicted as + versus ++. Nr2f1 and Nr2f2 in non-hematopoietic tissues were reviewed recently [16], therefore, only new and immune relevant references, as well as those for Nr2f6, are shown.
protein–protein interactions. Specifically, mechanistic studies will be able to determine the physiological consequences of transcriptional regulation and the concomitant modifications of NR2F6 in detail. Because nuclear receptors are well-established drug targets, pharmacological modulation of NR2F6 may represent an innovative therapeutic regimen for counteracting the pathogenic phenotype of Th17 cells.

Non-standard abbreviations used
AhR, arylhydrocarbon receptor; AICD, activation induced cell death; AP-1, activating protein-1; Bel6, B-cell lymphoma 6 protein; BMAL1/ARNTL, aryl hydrocarbon receptor nuclear translocator-like; C/EBPα, CCAAT/enhancer binding protein; ChIP, chromatin immunoprecipitation; CNS, conserved noncoding sequences; Circ, circadian locomotor output cycles kaput; DBD, DNA binding domain; EAE, experimental autoimmune encephalomyelitis; ER/NR3A, estrogen receptor; Foxo3a, the forkhead box sub-group O; GATA3, GATA binding protein 3; GM-CSF, granulocyte macrophage-colony stimulating factor; GR/NR3C1, gluco-corticoid receptor; HNF4/NR2A4, hepatocyte nuclear factor 4; HRE, hormone response element; IFN, interferon; IL, interleukin; LBD, ligand binding domain; LXR, liver X re-ceptor; LXRα, nuclear translocator-like; C/EBPα, CCAAT/enhancer binding protein; ChIP, chromatin immunoprecipitation; CNS, conserved noncoding sequences; Circ, circadian locomotor output cycles kaput; DBD, DNA binding domain; EAE, experimental autoimmune encephalomyelitis; ER/NR3A, estrogen receptor; Foxo3a, the forkhead box sub-group O; GATA3, GATA binding protein 3; GM-CSF, granulocyte macrophage-colony stimulating factor; GR/NR3C1, gluco-corticoid receptor; HNF4/NR2A4, hepatocyte nuclear factor 4; HRE, hormone response element; IFN, interferon; IL, interleukin; LBD, ligand binding domain; LXR, liver X re-ceptor; N-CoR, nuclear receptor co-repressor; NFAT, nuclear factor of activated T cells; NFκB, nuclear factor of κB; NR, nuclear receptor; NR4A2, nuclear receptor subfamily 4, group A, member 2; NR2F/COPU-TF, chicken ovalbumin upstream promoter transcription factor; PK, protein kinase; PPARγ/NR1C3, peroxisome proliferator activated receptor; RAR/NR1B1, retinoic acid receptor; REV-ERBα/ NR1D2, V-erb-a-related protein 1-related; RORγt, retinoid-related orphan receptor-gamma; Runx, runt related transcription factor; RXR/NR2B1, retinoid X receptor; SMRT, silencing mediator for retinoid and thyroid hormone recep-tors; STAT, signal-transducer and activator of transcription protein; T-beta, T-box transcription factor; TFκB, transforming growth factor-β; Th, T helper; TNF, tumor necrosis factor; TR, thyroid hormone receptor; VDR3/NR1I1, vitamin-D3 receptor; XRE, xenobiotic re-sponse elements.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
Both authors contributed equally to this review article. Both authors read and approved the final manuscript.

Acknowledgments
This work was supported by grants from the FWF Austrian Science Fund (P23537-B13 and P25044-B21).

Received: 16 April 2014 Accepted: 6 June 2014
Published: 12 June 2014

References
1. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM. The nuclear receptor superfamily: the second decade. Cell 1995, 83:835–839.
2. Evans RM. The steroid and thyroid hormone receptor superfamily. Science 1988, 240:899–905.
3. Peeran MA, Muscat GE. Orphan nuclear receptors and the regulation of nutrient metabolism: understanding obesity. Physiolology (Bethesda) 2012, 27:156–166.
4. Rhinn M, Dolle P. Retinoic acid signaling during development. Development 2012, 139:843–858.
5. Atlucci I, Leibowitz MD, Ogilvie KM, de Lera AR, Gronemeyer H. RAR and RXR modulation in cancer and metabolic disease. Nat Rev Drug Discov 2007, 6:793–810.
6. Hall JA, Grainger JR, Spencer SP, Belkaid Y. The role of retinoic acid in tolerance and immunity. Immunology 2011, 35:13–22.
7. Veldhoen M, Brucklacher-Waldert V. Dietary influences on intestinal immunity. Nat Rev Immunol 2012, 12:696–708.
8. Nagy L, Szentágothai J, Szatmari I, Szeles L. Nuclear hormone receptors enable macrophages and dendritic cells to sense their lipid environment and shape their immune response. Physiol Rev 2012, 92:739–789.
9. Gao GK, Saigo K. Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nat Rev Immunol 2010, 10:365–376.
10. Pereira FA, Qiu Y, Tsai MJ, Tsai SY. Chicken ovalbumin upstream promoter transcription factor (COPU-TF) expression during mouse embryogenesis. J Steroid Biochem Mol Biol 1995, 53:503–508.
11. Qiu Y, Krishnan V, Pereira FA, Tsai SY, Tsai MJ. Chicken ovalbumin upstream promoter-transcription factors and their regulation. J Steroid Biochem Mol Biol 1996, 56:81–85.
12. Park JL, Tsai SY, Tsai MJ. Molecular mechanism of chicken ovalbumin upstream promoter-transcription factor (COPU-TF) actions. Keio J Med 2003, 52:74–81.
13. Butler AJ, Parker MG. COPU-TF II homodimers are formed in preference to heterodimers with RXRα or TRβ in intact cells. Nucleic Acids Res 1995, 23:4143–4150.
14. Cooney AJ, Tsai SY, O’Malley BW, Tsai MJ. Chicken ovalbumin upstream promoter transcription factor (COPU-TF) dimers bind to different GGTCA promoters and their regulation. Mol Cell Biol 1992, 12:4153–4163.
15. Giguere V. Orphan nuclear receptors: from gene to function. Endocr Rev 1999, 20:689–725.
16. Lin PJ, Qin J, Tang K, Tsai SY, Tsai MJ. Coup D’etat: an orphan takes control. Endocr Rev 2011, 32:404–423.
17. Tang LS, Alger HM, Pereira FA. COPU-TF controls Notch regulation of hair cell and support cell differentiation. Development 2006, 133:3683–3693.
18. Pereira FA, Tsai MJ, Tsai SY. COPU-TF orphan nuclear receptors in development and differentiation. Cell Mol Life Sci 2000, 57:1388–1398.
19. Wacogne C, Oster H, Revel J-P, Alvarez-Bolado G, Eichele G. Abnormal development of the locus coeruleus in Ear2 (Nr2f6)-deficient mice. Development 2005, 132:625–635.
20. Weatherford ET, Liu X, Sigmund CD. Regulation of renin expression by the orphan nuclear receptors R221 and R226. Am J Physiol Renal Physiol 2012, 302:F1032–F1033.
21. Tan JJ, Ong SA, Chen KS. Rasd1 interacts with Ear2 (Nr2f6) to regulate renin transcription. BMC Mol Biol 2011, 12:4.
22. Zhang Y, Dufau MJ, Ear2 and Ear3/COPU-TF regulate transcription of the rat LH receptor. Mol Endocrinol 2001, 15:1891–1905.
23. Chu K, Zingg HH. The nuclear orphan receptors COPU-TFI and Ear-2 act as silencers of the human oxytocin gene promoter. J Mol Endocrinol 1997, 19:163–172.
24. Chu K, Boutin JM, Breton C, Zingg HH. Nuclear orphan receptors COPU-TFI and Ear-2: presence in oxytocin-producing uterine cells and functional interaction with the oxytocin gene promoter. Mol Cell Endocrinol 1998, 137:145–154.
25. Li XB, Jiao S, Sun H, Xue J, Zhao WT, Fan L, Wu GH, Fang J. The orphan nuclear receptor Ear2 is overexpressed in colorectal cancer and it regulates survivability of colon cancer cells. Cancer Lett 2011, 309:137–144.
26. Schote AB, Tumer JD, Schiltz JM, Muller CP: Nuclear receptors in human immune cells: expression and correlations. Mol Immunol 2007, 44:1436–1445.

27. Heng TS, Painter MW: The Immunological Genome Project: networks of gene expression in immune cells. Nat Immunol 2008, 9:1091–1094.

28. Wang LH, Tsi SY, Cook RG, Beattie WG, Tsai MJ: O’Malley BW: COUP transcription factor is a member of the steroid receptor superfamily. Nature 1997, 381:163–166.

29. Tsi SY, Tsi MJ: Chick ovalbumin upstream promoter-transcription factors (COPF-TFs): coming of age. Endocr Rev 1997, 18:229–240.

30. Giguere V, Yang N, Segui P, Evans RM: Identification of a new class of steroid hormone receptors. Nature 1988, 331:91–94.

31. Qiu Y, Pereira FA, DeMayo FJ, Lydon JP, Tsi SY, Tsi MJ: Null mutation of mCOUP-TFI results in defects in morphogenesis of the glossopharyngeal ganglion, axonal projection, and arborization. Genes Dev 1997, 11:1925–1937.

32. Bockout AL, Jeong Y, Downes M, Yu RT, Evans RM, Mangelsdorf DJ: Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell 2006, 126:789–799.

33. Pereira FA, Qiu Y, Zhou G, Tsi MJ, Tsi SY: The orphan nuclear receptor COUP-TFI is required for angiogenesis and heart development. Genes Dev 1999, 13:1037–1049.

34. Chen X, Qin J, Cheng CM, Tsi MJ, Tsi SY: COUP-TFI is a major regulator of cell cycle and Notch signaling pathways. Mol Endocrinol 2012, 26:1268–1277.

35. Penna G, Adorini L: Alpha,25-dihydroxyvitamin D3 inhibits leading to impaired alloreactive T cell activation. Proc Natl Acad Sci U S A 2009, 106:5819–5824.

36. Hermann-Kleiter N, Gruber T, Lutz-Nicoladoni C, Thuille N, Fresser F, Laci V: Nuclear receptors in human immune cells: expression and correlations. Autoimmunity 2006, 39:235–270.

37. Hermann-Kleiter and Baier G: http://www.biosignaling.com/content/12/1/38

38. Chen X, Qin J, Cheng CM, Tsi MJ, Tsi SY: COUP-TFI is a major regulator of cell cycle and Notch signaling pathways. Mol Endocrinol 2012, 26:1268–1277.

39. Xu Z, Yu S, Hsu CH, Eguchi J, Rosen ED: Microarray analysis identifies altered regulation of nuclear receptor family members in the pre-fibrotic state of multiple sclerosis. Neurobiol Dis 2010, 38:201–209.

40. Ehrlich M, Sanchez C, Shao C, Nishiyama R, Kehr J, Kucik R, Kubota T, Hanash SM: ICF, an immunodeficiency syndrome: DNA methyltransferase 3B involvement, chromosome anomalies, and gene dysregulation. Autoimmunity 2008, 41:253–271.

41. Katopodis A, Baier G: Gene expression analysis of peripheral T cell lymphoma, unspecifically, reveals distinct profiles and new potential therapeutic targets. J Clin Invest 2007, 117:823–834.

42. Vittet D, Brune DD, Zuniga-Pflucker JC, Wells RA: The orphan nuclear receptor COUPTFI is a major regulator of cell cycle and Notch signaling pathways. Mol Endocrinol 2012, 26:1268–1277.

43. Chen X, Qin J, Cheng CM, Tsi MJ, Tsi SY: COUP-TFI is a major regulator of cell cycle and Notch signaling pathways. Mol Endocrinol 2012, 26:1268–1277.

44. Vittet D, Brune DD, Zuniga-Pflucker JC, Wells RA: The orphan nuclear receptor COUPTFI is a major regulator of cell cycle and Notch signaling pathways. Mol Endocrinol 2012, 26:1268–1277.
controlled by preserved noncoding sequence 2. Immunity 2012, 36(1):23–31.
66. Yang XO, Pappu BP, Nuriev R, Akimzhanov A, Kang HS, Chung Y, Ma L, Shah B, Panopoulos AD, Schluns KS, WATowich SS, Tian Q, Jetten AM, Dong C. T helper 17 lineage differentiation is programmed by orphan nuclear receptors RORα and ROR-γt. Immunity 2008, 28:25–39.
67. Ivanov II, McDermott RS, Zhou L, Tadokoro CE, Legelley A, Lafaille JU, Cao DJ, Litmann DR. The orphan nuclear receptor RORγt directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006, 126:1211–1233.
68. Veldhoen M, Hirota K, Westendorf AM, Buer J, Dumoutier L, Renaud JC, Stocking B. The aryl hydrocarbon receptor links Th17 cell-mediated autoimmunity to environmental toxins. Nat. 2008, 453:106–109.
69. Klemm C, Raveney SJ, Klemann AK, Ozawa T, von Horsten S, Kretschman JE, Zang JZ, Yang JY, Kim CH, Kweon MN. Synthetic retinoid AM80 inhibits Th17 cells and ameliorates experimental autoimmune encephalomyelitis. Am J Pathol 2009, 174:2234–2245.
70. Klotz L, Burgdorf S, Dani I, Salio K, Flodmark J, Hucke S, Afflerjik J, Nowak M, Beyer M, Mayer G, Langhans B, Köglerich T, Waisman A, Eberl G, Schultz J, Farnum M, Kolansky W, Glass C, K Belize P. The nuclear receptor PPARγ selectively inhibits Th17 differentiation in a T cell-intrinsic fashion and suppresses CNS autoimmune. J Exp Med 2009, 206:2079–2089.
71. Cui G, Qin X, Wu L, Zhang Y, Sheng X, Yu Q, Sheng H, Xi B, Zhang J, Wang YC. Liver X receptor (LXR) mediates negative regulation of mouse and human Th17 differentiation. J Clin Invest 2011, 121:658–670.
72. Chen HR, Qian SY, Chang JH, Kim JD, Yang JY, Kim CH, Kweon MN. Downregulation of Th17 cells in the small intestine by disruption of gut flora in the absence of retinoic acid. J Immunol 2010, 184:679–6806.
73. Wust S, van den Brandt J, Tischner D, Keinan A, Tuckerman JP, Gil R, Luder F, Rechardt HM. Peripheral T cells are the therapeutic targets of glucocorticoid in experimental autoimmune encephalomyelitis. J Immunol 2008, 180:8634–8643.
74. Luhder F, Rechardt HM. Traditional concepts and future avenues of glucocorticoid action in experimental autoimmune encephalomyelitis and multiple sclerosis therapy. Crit Rev Immunol 2009, 29:255–273.
75. Wang C, Dehghani B, Li Y, Kaler LJ, Proctor T, Vandenbark AA, Offer BF. Membrane estrogen receptor regulates experimental autoimmune encephalomyelitis through up-regulation of programmed death-1. J Immunol 2009, 182:3304–3309.
76. Giguère V, Timi M, Flock G, Ong E, Evans RM, Otsukakoshi G. Isoform-specific amino-terminal domains dictate DNA-binding properties of RORα, a novel family of orphan hormone nuclear receptors. Genes Dev 1994, 8:538–553.
77. Kuroki J, Saito M, Sakurai H, Yamasaki M, Hasegawa K, Takemoto Y, Morita N, Kojima K, Takahashi T, Oda M, Matsui T. Nuclear receptor PPARγ regulates Th17 cell differentiation and ameliorates experimental autoimmune encephalomyelitis. Nature 2008, 453:106–109.
78. Klemann C, Raveney SJ, Klemann AK, Ozawa T, von Horsten S, Kretschman JE, Zang JZ, Yang JY, Kim CH, Kweon MN. Synthetic retinoid AM80 inhibits Th17 cells and ameliorates experimental autoimmune encephalomyelitis. Am J Pathol 2009, 174:2234–2245.
79. Sakhinia E, Glennie C, Hoyland JA, Menasce LP, Brady G, Miller C, Radford JA, Aiuto E, Verfaillie CM, Gessler M, Luttun A. COUP-TFII orchestrates venous and morphogenesis and coronary vessel development require chicken NR2F2. J Cell Sci 2013, 126:1146–1157.
80. Alkayed NH, Shimony JS, Vineyard M, Manwaring L, Kulkarni S, Shinnavi M. NR2F1 haploinsufficiency is associated with optic atrophy, dysmorphism and global developmental delay. J Lipid Res 2013, 54:377–388.
81. Alkayed NH, Shimony JS, Vineyard M, Manwaring L, Kulkarni S, Shinnavi M. NR2F1 haploinsufficiency is associated with optic atrophy, dysmorphism and global developmental delay. J Lipid Res 2013, 54:377–388.
82. Santarlasci V, Maggi L, Capone M, Querci V, Beltrame L, Cavalieri D, D’Alueto E, Cimaz R, Nibbio A, Locatelli F, De Palma R, Maggi E, Cosmi L, Romagnani S. Amelioration of experimental autoimmune encephalomyelitis by synthetic retinoid AM80 inhibits Th17 cells and ameliorates experimental autoimmune encephalomyelitis. J Immunol 2008, 180:8634–8643.
83. Felli MP, Vacca A, Meco D, Sereeini I, Farina AR, Marorder M, Mariniotti S, Pettangel E, Frati L, Gulino A. Retinoic acid-induced down-regulation of the interleukin-2 promoter via cis-regulatory sequences containing an octamer motif. Mol Cell Biol 1991, 11:4771–4778.
84. Wang W, Kimmel A, Kehrlie B, Bach H, Grub M, Durst R, Hornbach V, Marx N. LXR activation reduces proinflammatory cytokine expression in human CD4+ positive lymphocytes. Arterioscler Thromb Vasc Biol 2006, 26:1022–1028.
85. Alroy I, Towers TL, Freedman LP. Transcriptional repression of the interleukin-2 gene by vitamin D3: direct inhibition of NFATc1/AP-1 complex formation by a nuclear hormone receptor. Mol Cell Biol 1995, 15:789–789.
86. Bamberber CM, Else T, Bamberber AM, Bell FU, Schulte HM. Regulation of the human interleukin-2 gene by the α and β isoforms of the glucocorticoid receptor. Mol Cell Endocrinol 1997, 136:23–28.
87. Jeon MS, Ester C. The murine IL-2 promoter contains distal regulatory elements responsive to the Ah receptor, a member of the evolutionarily conserved SHEL-PAS transcription factor family. J Immunol 2000, 165:6975–6983.
88. Rochette-Egly C. Nuclear receptors: integration of multiple signaling pathways through phosphorylation. Cell Signal 2003, 15:355–366.
89. Gronemeyer H, Gustafsson JA, Laudet V. Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discov 2004, 3:505–514.
90. Popov VM, Wang C, Shiely LA, Rosenberg A, Li S, Nevaianien M, Fu M, Pestell RG. The functional significance of nuclear receptor acetylation. Steroids 2007, 72:221–230.
91. Kruse SW, Saino-Powell K, Zhou XE, Krestchman JE, Reynolds R, Vonrehn C, Xu Y, Wang L, Tsai SY, Tsai MJ, Hu XE. Identification of COUP-TFI as a retinoic acid-activated receptor. PloS Biol 2008, 6:e227.
92. Raj T, Rothamel K, Mostafavi S, Ye C, Lee MN, Repligo JM, Feng T, Lee M, Asinovski NF, Frohlich I, Imbroya S, Von Kopp A, Okada Y, Patsopoulos NA, Davis S, McCabe C, Paik H, Srivastava GP, Raychaudhuri S, Haffler DA, Koller D, Regev A, Hacohen N, Mathis D, Benoist C, Stanger BE, De Jager PL. Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes. Science 2014, 344:519–523.
93. Pops P, Bussy SA, Griffin PR. Targeting orphan nuclear receptors for treatment of metabolic diseases and autoimmune disease. Chem Biol 2012, 19:51–59.
94. Sákhinía E, Glennie C, Hoyland JA, Menasce LP, Brady G, Miller C, Radford JA, Byers Rj. Clinical quantitation of diagnostic and predictive gene expression levels in follicular and diffuse large B cell lymphoma by RT-PCR gene expression profiling. Blood 2007, 109:3922–3928.
95. Alkayed NH, Shimony JS, Vineyard M, Manwaring L, Kulkarni S, Shinnavi M. NR2F1 haploinsufficiency is associated with optic atrophy, dysmorphism and global developmental delay. Am J Med Genet A 2013, 161A:377–381.
96. Lin FJ, You LR, Yu CT, Hsu WH, Tsai MJ, Tsai SY. Targeting orphan nuclear receptors for treatment of metabolic diseases and autoimmune disease. Chem Biol 2012, 19:51–59.
97. Chekmenev D, Krull M, Hornischer K, Voss N, Stegmaier P, Lewicki-Potapov e227.
105. Hawkins SM, Loomans HA, Wan YW, Ghosh-Choudhury T, Coffey D, Xiao W, Liu Z, Sanghi-Haghpeykar H, Anderson ML: Expression and Functional Pathway Analysis of Nuclear Receptor NR2F2 in Ovarian Cancer. J Clin Endocrinol Metab 2013, 98(7):E1152–62.

106. Muscat GE, Eriksson NA, Byth K, Loli S, Graham D, Jindal S, Davis MJ, Clyne C, Funder JW, Simpson ER, Ragan MA, Kuczek E, Fuller PJ, Tilley WD, Leedman PJ, Clarke CL: Research resource: nuclear receptors as transcriptome: discriminant and prognostic value in breast cancer. Mol Endocrinol 2013, 27:350–365.

107. Ladias JA, Hadzopoulou-Cladaras M, Kardassis D, Cardot P, Cheng J, Zannis V, Cladaras C: Transcriptional regulation of human apolipoprotein genes ApoB, ApoCIII, and ApoAII by members of the steroid hormone receptor superfamily HNF-4, ARP-1, Ear2, and Ear3. J Biol Chem 1992, 267:15849–15860.

108. Cardot P, Chanmbaz J, Kardassis D, Cladaras C, Zannis VI: Factors participating in the liver-specific expression of the human apolipoprotein A-II gene and their significance for transcription. Biochemistry 1993, 32:9080–9093.

109. Li Y, Xia Y, Wang Y, Mao L, Gao Y, He Q, Huang M, Chen S, Hu B: Sonic hedgehog (Shh) regulates the expression of angiogenic growth factors in oxygen-glucose-deprived astrocytes by mediating the nuclear receptor NR2F2. Mol Neurobiol 2013, 47:967–975.

110. Krizhanovsky V, Soreq L, Kliminski V, Ben-Arie N: Math1 target genes are enriched with evolutionarily conserved clustered E-box binding sites. J Mol Neurosci 2006, 28:211–229.

111. Shi M, Hu ZL, Zheng MH, Song NN, Huang Y, Zhao G, Han H, Ding YQ: Notch-Rbpj signaling is required for the development of noradrenergic neurons in the mouse locus coeruleus. J Cell Sci 2012, 125:4320–4332.

112. Chew LJ, Huang F, Boutin JM, Gallo V: Identification of nuclear orphan receptors as regulators of expression of a neurotransmitter receptor gene. J Biol Chem 1999, 274:29366–29375.

113. Liu X, Huang X, Sigmund CD: Identification of a nuclear orphan receptor (Ear2) as a negative regulator of renin gene transcription. Circ Res 2003, 92:1033–1040.

doi:10.1186/1478-811X-12-38
Cite this article as: Hermann-Kleiter and Baier: Orphan nuclear receptor NR2F6 acts as an essential gatekeeper of Th17 CD4+ T cell effector functions. Cell Communication and Signaling 2014, 12:38.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit